Leishmaniasis as an opportunistic infection in HIV-infected patients: Determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterreanean region

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 24, Issue 6, 2005, Pages 411-418

  Pasquau, F ^a   Ena, J ^a   Sanchez, R ^b   Cuadrado, J M ^c   Amador, C ^a   Flores, J ^d   Benito, C ^a   Redondo, C ^e   Lacruz, J ^f   Abril, V ^g   Onofre, J ^h  

^a Marina Baixa Hospital   (Spain)

^b University General Hospital   (Spain)

^c HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^d HOSPITAL ARNAU DE VILANOVA   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^h Allergy Section   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE; PENTAMIDINE;

AMASTIGOTE; ASPIRATION; BONE MARROW; CELL COUNT; CELL SURVIVAL; DISEASE ASSOCIATION; DISEASE COURSE; FOLLOW UP; HEPATOMEGALY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MORTALITY; PATIENT CARE; PRIORITY JOURNAL; PROPHYLAXIS; RELAPSE; REVIEW; RISK FACTOR; SPAIN; SPLENOMEGALY; VISCERAL LEISHMANIASIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; FEMALE; HUMANS; LEISHMANIASIS, VISCERAL; MALE; MEDITERRANEAN REGION; RECURRENCE; RISK FACTORS;

EID: 21644471998     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-005-1342-6     Document Type: Review

References (52)

1. World Health Organization (1999) Leishmania/HIV co-infection, south-western Europe, 1990-1998. Retrospective analysis of 965 cases. Wkly Epidemiol Rec 74:365-375
2. Desjeux P, Alvar J (2003) Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol 97 (Suppl 1):3-15
3. Alvar J, Canavate C, Gutierrez-Solar B, Jimenez M, Laguna F, Lopez-Velez R, Molina R, Moreno J (1997) Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 10:298-319
4. Lopez-Velez R, Perez-Molina JA, Guerrero A, Baquero F, Villarrubia J, Escribano L, Bellas C, Perez-Corral F, Alvar J (1998) Clinicoepidemiologic characteristics, prognostic factors and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain. Am J Trop Med Hyg 58:436-443
5. Medrano FJ, Hernandez-Quero J, Jimenez E, Pineda JA, Rivero A, Sanchez-Quijano I, Vélez D, Viciana P, Castillo R, Reyes MJ, Carvajal F, Leal M, Lissen E (1992) Visceral leishmaniasis in HIV-infected individuals: a common opportunistic infection in Spain?. AIDS 6:1499-1503
6. Centers for Disease Control (1987) Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Mor Mortal Wkly Rep 36 (no. 1S):526
7. Martinez P, De la Vega E, Laguna F, Soriano V, Puente S, Moreno V, Sentchordi MJ, García-Aguado C, Gonzalez-Lahoz J (1993) Diagnosis of visceral leishmaniasis in HIV-infected individuals using peripheral blood smears. AIDS 7:227-230
8. Medrano FJ, Jiménez-Mejías E, Calderon E, Regordán C, Leal M (1993) An easy and quick method for the diagnosis of visceral leishmaniasis in HIV-1 infected individuals. AIDS 13:1399
9. Pintado V, Martin-Rabadan P, Rivera ML, Moreno S, Bouza E (2001) Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore) 80:54-73
10. Riera M, Altes J, Homar F, Picco G, Salas A, Leyes M, Cifuentes C, Artigues A, Villalonga C (1996) Fever of unknown origin in patients with HIV infection. Enferm Infecc Microbiol Clin 14:581-585
11. Lozano F, Torre-Cisneros J, Bascunana A, Polo J, Viciana P, García-Ordoñez MA, Hernandez-Quero J, Marquez M, Vergara A, Diez F, Pujol E, Torres-Tortosa M, Pasquau J, Hernandez-Burruezo JJ, Suarez I (1996) Prospective evaluation of fever of unknown origin in patients infected with the human immunodeficiency virus. Grupo Andaluz para el Estudio de las Enfermedades Infecciosas. Eur J Clin Microbiol Infect Dis 15:705-711
12. Knobel H, Supevía A, Salvado M, Gimeno JL, Lopez-Colomes JL, Saballs R Drobnic L, Diaz A (1996) Fever of unknown origin in patients with human immunodeficiency virus infection. Study of 100 cases. Rev Clin Esp 196:349-353
13. Benito N, Nuñez A, De Gorgolas M, Esteban J, Calabuig T, Rivas MC, Fernandez-Guerrero ML (1997) Bone marrow biopsy in the diagnosis of fever of unknown origin in patients with acquired immunodeficiency syndrome. Arch Inter Med 157:1577-1580
14. Rosenthal E, Marty P, Del Giudice R Pradier C, Ceppi C, Gastaut JA, Le Fichoux Y, Cassuto JP (2000) HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania. Clin Infect Dis 31:1093-1095
15. Cascio A, Antinori S, Campisi G, Mancuso S (2000) Oral leishmaniasis in an HIV-infected patient. Eur J Clin Microbiol Infect Dis 19:651-653
16. Weber R, Ledergerber B, Zbinden R (1999) Enteric infections and diarrhea in human immunodeficiency virus-infected persons: prospective community-based cohort study. Swiss HIV cohort study. Arch Intern Med 159:1473-1480
17. Gari-Toussaint M, Lelievre A, Marty P, Le Fichoux Y (1994) Contribution of serological test to the diagnosis of visceral leishmaniasis in patients infected with the human immunodeficiency virus. Trans R Soc Trop Med Hyg 88:301-302
18. Zijlstra EE, Ali SM, El-Hassan AM, El-Toum IA, Satti M, Ghalib HW, Kager PA (1992) Kala-Azar: a comparative study of parasitological methods and the direct agglutination test in diagnosis. Trans R Soc Trop Med Hyg 86:505-507
19. Berhe N, Hailu A, Wolday D, Negesse Y, Venini P, Frommel D (1995) Ethiopian visceral leishmaniasis patients co-infected with human immunodeficiency virus. Trans R Soc Trop Med Hyg 89:205-207
20. World Health Organization (1997) Leishmania/HTV co-infection. Epidemiological analysis of 692 retrospective cases. Wkly Epidemiol Rec 72:49-54
21. Pizzuto M, Piazza M, Senese D (2001) Role of PCR in diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type 1. J Clin Microbiol 39:357-361
22. Bossolasco S, Gaiera G, Olchini D, Gulletta M, Martello L, Bestetti A, Bossi L, Germagnoli L, Lazzarin A, Foppa C, Cinque P (2003) Real-time PCR assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis. J Clin Microbiol 41:5080-5084
23. Cruz I, Canavate C, Rubio JM, Morales MA, Chicharro C, Laguna I, Mejias M, Sirera G, Videla S, Alvar J (2002) A nested polymerase chain reaction (Ln-PCR) for diagnosing and monitoring Leishmania infantum infection in patients co-infected by human immunodeficiency virus. Trans R Soc Trop Med Hyg 96 (Suppl 1):185-189
24. Mary C, Lamouroux D, Dunan S, Quilici M (1992) Western blot analysis of antibodies to Leishmania infantum antigens: potential of the 14-KD antigens for diagnosis and epidemiologic purposes. Am J Trop Med Hyg 47:764-771
25. Rosenthal E, Marty P (2003) Recent understanding in the treatment of visceral leishmaniasis. J Postgrad Med 49:61-68
26. Laguna F (2003) Treatment of leishmaniasis in HIV-positive patients. Ann Trop Med Parasitol 97 (Suppl 1):135-142
27. Herwaldt B, Berman J (1992) Recommendations for treating leishmaniasis with sodium stibogluconate and review of pertinent clinical studies. Am J Trop Med Hyg 46:296-306
28. Delgado J, Macías J, Pineda JA, et al (1999) High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. Am J Trop Med Hyg 61:766-769
29. Faraut-Gambarelli F, Piarroux R, Deniau M, et al (1997) In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimicrob Agents Chemother 41:827-830
30. Carrio J, Riera C, Gállego M, Ribera E, Portús M (2001) In vitro susceptibility of Leishmania infantum to meglumine antimoniate in isolates from repeated leishmaniasis episodes in HIV-coinfected patients. J Antimicrob Chemother 47:120-121
31. Laguna F, Lopez-Velez R, Pulido F, Salas A, Torre-Cisneros J, Torres F, Medrano FJ, Sanz J, Pico G, Gomez-Rodrigo J, Pasquau J, Alvar J (1999) Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. AIDS 13:1063-1069
32. Davidson RN, Di Martino L, Gradoni L, et al (1996) Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 22:938-943
33. Berman JD (1999) U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 28:49-51
34. Laguna F, Videla S, Jimenez-Mejias E, Sirera G, Torres-Cisneros J, Ribera E, Prados D, Clotet B, Sust M, Lopez-Velez R, Alvar J (2003) Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. J Antimicrob Chemother 52:464-468
35. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR Buffels R (2003) Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 37:800-804
36. Jha TK, Sundar S, Thakur CP, et al (1999) Miltefosine, an oral agent for the treatment of Indian visceral leishmaniasis. N Engl J Med 341:1795-1800
37. Sundar S, Rosenkaimer F, Makharia MK, et al (1998) Trial of oral miltefosine for visceral leishmaniasis. Lancet 352:1821-1823
38. Sundar S, Makharia MK, More DK, Agrawal G, Voss A, Fischer C, et al (2000) Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin Infect Dis 31:1110-1113
39. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, et al (2002) Oral miltefosine for Indian leishmaniasis. N Engl J Med 347:1739-1746
40. Thakur CR Sinha PK, Singh RK, Hassan SM, Narain S (2000) Miltefosine in a case of visceral leishmaniasis with HIV co-infection, and rising incidence of this disease in India. Trans R Soc Trop Med Hyg 94:696-697
41. Laguna F, Estal P, Moya-Mir MS (1997) Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. Am J Med 102:222
42. López-Vélez R, Videla S, Marquez M, Boix V, Jiménez-Mejías E, Górgolas M, Arribas JR, Salas A, Laguna F, Sust M, Canavate C, Alvar J (2004) Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 53:540-543
43. Montana M, Chochoi N, Monges P, Ravaux I, Faraut F, Gensollen S, Timon-David P, Gallais H (2004) Liposomal amphotericin B in secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. Pathol Biol (Paris) 52:66-75
44. Kovacs J, Masur H (2000) Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 342:1416-1429
45. U.S. Public Health Service/Infectious Diseases Society of America (USPHS/IDSA) (2001) Guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. USPHS/IDSA Prevention of Opportunistic Infections Working Group, http://www.cdc.gov/hiv. Cited 28 November 2001
46. Rosenthal E, Tempesta S, Pascal del Giudice, Marty P, Desjeux P, Pradier C, et al (2001) Declining incidence of visceral leishmaniasis in HIV-infected patients in the era of highly active antiretroviral therapy. AIDS 15:1184-1185
47. Villanueva JL, Alarcon A, Bernabeu-Witell M, Cordero E, Prados D, Regordan C, Alvar J (2000) Prospective evaluation and follow-up of European patients with visceral leishmaniasis and HIV-1 coinfection in the era of highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis 19:798-801
48. Soriano V, Dona C, Rodriguez-Rosado R, Barreiro P, González-Lahoz J (2000) Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 14:383-386
49. Mira JA, Corzo J, Rivero A, Macias J, Lozano de Leon F, Torre-Cisneros J, Gomez-Mateos J, Jurado R, Pineda J (2004) Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. Am J Trop Med Hyg 70:298-301
50. De la Rosa R, Pineda JA, Delgado J, Macias J, Morillas F, Mira JA, Sanchez-Quijano A, Leal M, Lissen E (2002) Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy. J Clin Microbiol 40:762-767
51. Merino E, Sanchez J, Boix V, Pasquau F, Cuadrado JM, Ena J, Jover F, De la Cruz J, Portilla J (2001) Visceral leishmaniasis relapses in HIV patients in spite of successful HAART. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections. Chicago, USA. Abstract no.549
52. Lopez-Velez R (2003) The impact of highly active antiretroviral therapy (HAART) on leishmaniasis in Spanish patients who are co-infected with HIV. Ann Trop Med Parasitol 97 (Suppl 1):143-147